post-exposure-prophylaxis

Xocova clears the FDA. What it actually prevents is the smaller story.

The FDA approved Shionogi's ensitrelvir for post-exposure COVID prevention, citing a 67% relative risk reduction. Look at what the trial actually measured and a different story comes into focus.